| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ALNY | Common Stock | Award | $0 | +3K | +25.73% | $0.00 | 14.7K | Nov 25, 2024 | Direct | F1 |
| transaction | ALNY | Common Stock | Sale | -$6.44K | -26 | -0.18% | $247.77 | 14.6K | Nov 26, 2024 | Direct | F2, F3 |
| transaction | ALNY | Common Stock | Sale | -$53.7K | -215 | -1.47% | $249.60 | 14.4K | Nov 26, 2024 | Direct | F2, F4 |
| transaction | ALNY | Common Stock | Sale | -$79.7K | -318 | -2.21% | $250.68 | 14.1K | Nov 26, 2024 | Direct | F2, F5 |
| transaction | ALNY | Common Stock | Sale | -$208K | -826 | -5.86% | $251.42 | 13.3K | Nov 26, 2024 | Direct | F2, F6 |
| transaction | ALNY | Common Stock | Sale | -$21.2K | -84 | -0.63% | $252.27 | 13.2K | Nov 26, 2024 | Direct | F2, F7 |
| Id | Content |
|---|---|
| F1 | On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting FDA acceptance of a new drug application submitted for regulatory approval for a therapeutic to treat ATTR amyloidosis with cardiomyopathy after receipt of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 study, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on November 22, 2024. |
| F2 | Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. |
| F3 | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $247.76 to $248.67. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F4 | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $249.00 to $250.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F5 | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $250.05 to $251.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F6 | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $251.07 to $252.06. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F7 | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $252.09 to $252.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |